There's Reason For Concern Over Natera, Inc.'s (NASDAQ:NTRA) Price
May 18
Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 19, 2025
DataAggregated Company Financials
Companies564
- 7D1.4%
- 3M-10.4%
- 1Y-14.7%
- YTD-7.1%
The Biotech industry is up 1.4% in the last week, with Gilead Sciences up 5.8%. However, the industry is down 15% over the past year. Looking forward, earnings are forecast to grow by 24% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 19 May 2025 | US$895.2b | US$155.9b | -US$24,392,718,921.60 | 16.3x | -36.7x | 5.7x |
| Wed, 16 Apr 2025 | US$764.9b | US$119.2b | -US$36,605,024,519.56 | 20.2x | -20.9x | 6.4x |
| Fri, 14 Mar 2025 | US$841.0b | US$118.5b | -US$37,519,343,472.27 | 17.8x | -22.4x | 7.1x |
| Sun, 09 Feb 2025 | US$840.3b | US$117.3b | -US$30,891,273,158.04 | 17.2x | -27.2x | 7.2x |
| Tue, 07 Jan 2025 | US$968.2b | US$149.6b | -US$26,363,916,330.88 | 16.7x | -36.7x | 6.5x |
| Thu, 05 Dec 2024 | US$1.0t | US$150.0b | -US$26,559,447,157.66 | 17.4x | -38.6x | 6.8x |
| Sat, 02 Nov 2024 | US$1.1t | US$147.4b | -US$30,526,626,860.52 | 17.5x | -34.7x | 7.2x |
| Mon, 30 Sep 2024 | US$893.6b | US$113.2b | -US$36,006,680,210.71 | 21.3x | -24.8x | 7.9x |
| Wed, 28 Aug 2024 | US$912.3b | US$113.2b | -US$35,873,175,029.80 | 23.7x | -25.4x | 8.1x |
| Fri, 26 Jul 2024 | US$1.2t | US$164.3b | -US$28,279,434,472.09 | 28.4x | -42.8x | 7.4x |
| Sun, 23 Jun 2024 | US$1.2t | US$164.4b | -US$27,942,490,934.12 | 28.1x | -41.4x | 7x |
| Tue, 21 May 2024 | US$1.1t | US$164.6b | -US$26,833,016,716.77 | 24.2x | -42.8x | 7x |
| Thu, 18 Apr 2024 | US$1.1t | US$164.2b | -US$23,335,767,618.82 | 20.4x | -46.2x | 6.6x |
| Sat, 16 Mar 2024 | US$1.2t | US$167.4b | -US$22,091,319,843.29 | 13.9x | -53.3x | 7x |
| Mon, 12 Feb 2024 | US$1.2t | US$169.3b | -US$26,263,046,791.87 | 19.8x | -44.2x | 6.9x |
| Wed, 10 Jan 2024 | US$1.4t | US$204.8b | -US$22,502,246,114.00 | 20.4x | -64.2x | 7.1x |
| Fri, 08 Dec 2023 | US$1.3t | US$204.6b | -US$22,051,399,456.00 | 19.3x | -58.1x | 6.3x |
| Sun, 05 Nov 2023 | US$1.2t | US$206.7b | -US$20,535,513,316.00 | 18.8x | -60.4x | 6x |
| Tue, 03 Oct 2023 | US$1.3t | US$207.3b | -US$13,085,561,707.00 | 16.8x | -96x | 6.1x |
| Thu, 31 Aug 2023 | US$1.3t | US$207.7b | -US$12,462,393,654.00 | 17.6x | -103.8x | 6.2x |
| Sat, 29 Jul 2023 | US$1.1t | US$186.0b | -US$15,177,418,533.00 | 14.7x | -74.9x | 6.1x |
| Mon, 26 Jun 2023 | US$1.1t | US$186.2b | -US$16,162,116,001.00 | 13.6x | -70.3x | 6.1x |
| Wed, 24 May 2023 | US$1.2t | US$186.1b | -US$15,836,040,128.00 | 12.9x | -73.2x | 6.2x |
| Fri, 21 Apr 2023 | US$1.2t | US$198.4b | -US$3,235,324,680.00 | 13.6x | -364.2x | 5.9x |
| Sun, 19 Mar 2023 | US$1.1t | US$199.2b | -US$3,885,938,113.00 | 13.2x | -287.6x | 5.6x |
| Tue, 14 Feb 2023 | US$1.2t | US$202.8b | -US$239,371,196.00 | 16.5x | -4869.1x | 5.7x |
| Thu, 12 Jan 2023 | US$1.2t | US$203.6b | US$1.7b | 14.3x | 687.1x | 5.7x |
| Sat, 10 Dec 2022 | US$1.1t | US$202.7b | US$1.4b | 14.6x | 811.3x | 5.6x |
| Mon, 07 Nov 2022 | US$1.1t | US$204.3b | US$3.8b | 13.4x | 285.1x | 5.3x |
| Wed, 05 Oct 2022 | US$1.1t | US$206.5b | US$5.6b | 15.6x | 189.7x | 5.2x |
| Fri, 02 Sep 2022 | US$1.1t | US$206.1b | US$7.2b | 15.3x | 147.2x | 5.1x |
| Sun, 31 Jul 2022 | US$1.1t | US$212.0b | US$11.3b | 15.6x | 93.2x | 5x |
| Tue, 28 Jun 2022 | US$1.1t | US$212.6b | US$11.1b | 16x | 94.4x | 4.9x |
| Thu, 26 May 2022 | US$1.0t | US$212.6b | US$11.1b | 15.4x | 90.6x | 4.7x |
Price to Earnings Ratio
90.6x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 9.8% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 2.94% | |
| Healthcare | -1.42% | |
| Biotech | 1.44% | |
| Biotech | 1.44% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| GILD Gilead Sciences | US$102.50 | 5.8% +US$7.0b | 51.4% | PE21.4x | |
| ALNY Alnylam Pharmaceuticals | US$285.31 | 13.6% +US$4.5b | 91.0% | PS15.8x | |
| EXEL Exelixis | US$45.40 | 25.5% +US$2.4b | 117.1% | PE19.2x | |
| REGN Regeneron Pharmaceuticals | US$594.32 | 3.2% +US$2.0b | -39.8% | PE14x | |
| ACAD ACADIA Pharmaceuticals | US$22.26 | 27.6% +US$806.7m | 50.5% | PE16.3x |
